New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Jay Leno Undergoes Surgery for ‘Significant’ Burns From Car Fire
The comedian and TV host sustained mostly second-degree burns to his face, hands and chest. He was ‘cracking jokes’ after surgery to remove damaged skin tissue and place skin grafts, his doctor said. #surgery #tvhost #comedian #doctor (Source: Reuters: Health)
Source: Reuters: Health - November 17, 2022 Category: Consumer Health News Source Type: news
Jay Leno may need skin grafts after suffering third-degree burns in car fire
The “Jay Leno’s Garage” host, who is expected to spend five to 10 days in the hospital, credited his friend with saving him after he caught on fire. #skingrafts #jayleno #jaylenosgarage #hospital (Source: Reuters: Health)
Source: Reuters: Health - November 15, 2022 Category: Consumer Health News Source Type: news
Jay Leno suffered third-degree burns in car fire, may need skin grafts
Jay Leno revealed he suffered third-degree burns and may need skin grafts after a 115-year-old car burst into flames in his famous LA garage, where he was rescued by a quick-thinking friend. #jayleno #skingrafts #garage (Source: Reuters: Health)
Source: Reuters: Health - November 15, 2022 Category: Consumer Health News Source Type: news
An Autologous Homologous Skin Construct for Acute Wounds An Autologous Homologous Skin Construct for Acute Wounds
In this paper, the authors describe the use of an autologous homologous skin construct in two surgical patients who were unable to undergo skin grafting.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2022 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Cell therapy could improve bone marrow transplant safety
FINDINGSUCLA researchers report a step forward in the development of an “off-the-shelf” cell therapy that could reduce the severity of graft-versus-host disease in people receiving donor bone marrow transplants for the treatment of blood cancers such as leukemia and lymphoma.The method utilizes rare and powerful immune cells called invariant natural killer T, or iNKT, cells, which can reduce and delay the transplanted cells ’ attacks on healthy tissue without compromising these cells’ cancer-fighting abilities. The iNKT cells are produced from blood-forming stem cells obtained from donated umbilical cord blood and ...
Source: UCLA Newsroom: Health Sciences - September 6, 2022 Category: Universities & Medical Training Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Use of composite acellular dermal matrix-ultrathin split-thickness skin in hand hot-crush injuries: a one-step grafting procedure - Fan Y, Pan Y, Chen C, Cui S, Li J, Jin G, Huang N, Xu S.
BACKGROUND: Hot-crush injuries to the hands can be devastating, and early debridement and coverage with skin autograft remains the golden standard of wound treatment. However, this type of treatment is not feasible or unlikely to succeed due to limited don... (Source: SafetyLit)
Source: SafetyLit - August 3, 2022 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news
Atrium Health ’s Sanger Heart & Vascular Institute first in the world to use implantable fish-skin grafting in reconstructive surgery
Atrium Health ’s Sanger Heart& Vascular Institute has received a Center of Excellence designation from Kerecis ®, a medical device manufacturer pioneering the use of fish skin and fatty acids in cellular therapy, tissue regeneration and protection.
Sanger Heart& Vascular Institute surgeon Dr. Hector Crespo Soto is the first physician in the world to use SurgiBind implantable reinforcement fish-skin commercially. With this designation, Crespo Soto and the team at Sanger Heart& Vascular Institute … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 1, 2022 Category: Biotechnology Authors: Atrium Health Source Type: news
New IMBRUVICA ® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line tre...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Omega-3-Rich Fish Skin for Chronic Diabetic Foot Ulcers Omega-3-Rich Fish Skin for Chronic Diabetic Foot Ulcers
Might the application of a fish skin graft help promote healing in chronic diabetic foot ulcers? How does this compare to standard of care treatments?Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 6, 2022 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Phase 3 SHINE Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
This study is one of the largest clinical trials ever conducted in first-line MCL and the first for a Bruton’s tyrosine kinase inhibitor (BTKi).[1] The data are being presented in an oral session and featured in a press briefing during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, and were published in The New England Journal of Medicine today. The data will also be presented as an oral presentation at the 2022 European Hematology Association (EHA) Annual Congress. MCL is a type of aggressive, rare non-Hodgkin lymphoma (NHL) that is incurable and difficult to treat.[2] It commonly affects people o...
Source: Johnson and Johnson - June 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
